Apixaban Starting Dose for a 75-Year-Old Male
For a 75-year-old male, start apixaban at 5 mg twice daily unless he meets at least TWO of the following three criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (133 μmol/L)—in which case use 2.5 mg twice daily. 1
Dose Selection Algorithm
The appropriate apixaban dose depends on the indication and specific patient characteristics:
For Atrial Fibrillation (Stroke Prevention)
Standard dose: 5 mg twice daily 1
Reduced dose: 2.5 mg twice daily if the patient has at least TWO of these criteria 2, 3, 1:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL (133 μmol/L)
Critical point: At age 75, this patient does NOT automatically qualify for dose reduction based on age alone. You must assess all three criteria and only reduce the dose if TWO or more are present 4.
For Venous Thromboembolism (DVT/PE Treatment)
Initial 7 days: 10 mg twice daily
After 7 days: 5 mg twice daily 5, 1
There are no dose reduction criteria for VTE treatment based on age, weight, or renal function in the standard regimen 5.
For VTE Prevention After Orthopedic Surgery
2.5 mg twice daily starting 12-24 hours post-surgery 1
Renal Function Considerations
Assess creatinine clearance using the Cockcroft-Gault equation 6:
- CrCl >50 mL/min: Standard dosing applies
- CrCl 30-50 mL/min: For atrial fibrillation, continue 5 mg twice daily unless the patient also meets the other dose reduction criteria (age ≥80 AND/OR weight ≤60 kg) 7
- CrCl 15-29 mL/min: Very limited data; apixaban may be used with caution at 5 mg twice daily for atrial fibrillation, but consider 2.5 mg twice daily if bleeding risk is high 7
- CrCl <15 mL/min or dialysis: No robust trial data; use with extreme caution 6
Common Dosing Pitfalls to Avoid
Do not reduce the dose based on a single criterion. Research shows that patients with only one dose-reduction criterion (such as age 75-79 years alone) have similar efficacy and safety with the standard 5 mg twice daily dose compared to those with no risk factors 4. Inappropriate dose reduction leads to underdosing and increased thromboembolic risk 8, 9.
Do not use serum creatinine alone without calculating creatinine clearance. The dose reduction criterion is serum creatinine ≥1.5 mg/dL, but you should also calculate CrCl to fully assess renal function 7.
Avoid empiric dose reduction in elderly patients. Age 75 does not meet the age criterion (which is ≥80 years). Studies demonstrate that patients aged 75-79 with normal weight and renal function benefit from standard dosing 4, 9.
Management Strategy
- Determine the indication: Atrial fibrillation, VTE treatment, or VTE prophylaxis
- Assess all three dose-reduction criteria:
- Confirm exact age (≥80 years?)
- Measure body weight (≤60 kg?)
- Check serum creatinine (≥1.5 mg/dL?) and calculate CrCl
- Apply the two-out-of-three rule for atrial fibrillation dosing
- Reassess renal function at least annually or when clinically indicated 6
- Check for drug interactions: Reduce dose by 50% if using combined P-glycoprotein and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) with standard-dose apixaban; avoid these drugs entirely if already on 2.5 mg twice daily 1
Monitoring and Follow-Up
While routine therapeutic drug monitoring is not required for apixaban, consider measuring plasma concentrations in high-risk scenarios such as extreme age (>85 years), fluctuating renal function, or unexplained bleeding 10.
Recheck renal function annually or more frequently if the patient has CrCl 30-50 mL/min, as fluctuations near dosing cutoffs may necessitate dose adjustments 11.
For patients with atrial fibrillation, apixaban demonstrates superior safety compared to warfarin with significantly lower rates of intracranial hemorrhage (HR 0.51) and similar or better efficacy for stroke prevention 3. Recent data also suggest apixaban may have lower bleeding risk than rivaroxaban in VTE treatment 12.